Browse All

Current Filters

CLEAR FILTER x

TITLE

The Effects of Lecanemab Treatment on Soluble CSF Aß Protofibrils (PF) in Clarity AD

Clinical Profile for Lecanemab Subcutaneous Formulation for Treatment Initiation and Maintenance in Early Alzheimer’s Disease (AD)

The Lecanemab Clarity AD Open-label Extension in Early Alzheimer’s Disease: Initial Findings from the 48-month Analysis

Baseline Characteristics and Preliminary Safety from a Multicenter, Safety Surveillance Study of Lecanemab Treatment for Alzheimer’s Disease in Real-world Clinical Practice Using Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET) Registry